Monitor for any material updates from the NAVREF conference, particularly enrollment progress in the FlowPath Lung study or new commercial traction with the VA. No immediate catalyst — this is a standard scientific conference presentation.
Price Chart
Executive Summary
bioAffinity Technologies filed an 8-K announcing it will present two posters on its CyPath Lung diagnostic at the NAVREF Annual Conference (Sept 27-30, 2026). The posters cover clinical case studies and an ongoing 2,000-patient longitudinal study in veteran/military populations. This is a routine conference presentation with no new financial data, no material clinical results, and no regulatory or commercial catalyst.
Key Facts
- Presenting two posters on CyPath Lung at NAVREF 2026 Annual Conference, Sept 27-30, 2026 in Arlington, VA
- Poster #1 presents three clinical cases using CyPath Lung in high-risk patients with indeterminate pulmonary nodules
- Poster #2 describes the ongoing FlowPath Lung study, a 2,000-patient longitudinal study in veteran/military populations
- FlowPath Lung study enrolling at 12 VA medical centers and two military hospitals
- CyPath Lung previously reported 92% sensitivity, 87% specificity, and 99% negative predictive value in patients with nodules ≤20 mm
- First joint engagement with new distribution partner AvMEDICAL at the federal healthcare market
Financial Impact
No financial figures reported. Third-party economic analysis cited in the poster estimates potential savings of 'thousands of dollars per person and hundreds of millions of dollars overall' — this is not company guidance and is forward-looking.
Risk Factors
- CyPath Lung is marketed as a Laboratory Developed Test (LDT) under CLIA, not FDA-approved — regulatory pathway risk
- The 92%/87%/99% performance data is from a specific nodule-size cohort and may not generalize to broader populations
- Company remains pre-profitability and requires additional financing per forward-looking statement risk factors
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-043654 |
| Exhibit: ex99-1.htm | 0001493152-26-043654 |
| Document: 0001493152-26-043654-index-headers.html | 0001493152-26-043654 |
| Document: 0001493152-26-043654-index.html | 0001493152-26-043654 |
| Document: 0001493152-26-043654.txt | 0001493152-26-043654 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | DEF 14A | $2.81 | awaiting T+1 | — | $2.83 (+0.71%) |
Oct 15, 2026 11d ago | 8-K | $3.96 $3.73 | ▼ −5.81% | ▼ −4.70% | $2.83 (−28.54%) |
Oct 13, 2026 13d ago | 8-K | $3.63 $3.56 | ▼ −1.79% | ▼ −0.71% | $2.83 (−21.93%) |
Oct 9, 2026 17d ago | 8-K | $3.90 $3.63 | ▲ +7.05% | ▲ +7.04% | $2.83 (+27.44%) |
Oct 9, 2026 17d ago | 424B5 | $4.73 $3.90 | ▲ +17.46% | ▲ +17.40% | $2.83 (+40.11%) |
Oct 9, 2026 17d ago | 424B5 | $4.73 $3.90 | ▼ −17.46% | ▼ −17.40% | $2.83 (−40.11%) |
Oct 8, 2026 19d ago | 8-K | $5.64 $4.73 | ▼ −16.22% | ▼ −16.82% | $2.83 (−49.82%) |
Oct 6, 2026 21d ago | 8-K | $6.06 $6.16 | ▲ +1.65% | ▲ +1.89% | $2.83 (−53.30%) |
Sep 30, 2026 27d ago | 8-K | $6.56 $6.15 | ▼ −6.33% | ▼ −6.50% | $2.83 (−56.86%) |
Sep 22, 2026 5w ago | 8-K | $8.56 $7.94 | ▼ −7.19% | ▼ −6.47% | $2.83 (−66.92%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers